30
CARDIOVASCULAR
hamburger

XIENCE Skypoint™ Stent: Better Expansion, Excellent Deliverability, and Trusted Patient Outcomes2-4

As the latest generation in the XIENCE™ family of stents, the stent platform that consistently delivers successful patient outcomes – not only in the cath lab, but also long-term.4 This stent also offers:

  • The broadest expansion range among XIENCE™ Stents2
  • The largest size range for a single XIENCE™ product, from 8 mm to 48 mm2
Xience Skypoint
XIENCE Skypoint Stent has new features to aid in deliverability and pushability.

Stent Choice Matters

During percutaneous coronary interventions (PCI), small differences between stents can be the determining factor for the patient’s acute and long-term outcomes.4 XIENCE Skypoint™ Stent has a number of new features that offer broader treatment options to interventional cardiologists (ICs).

Updated features include:

  • Larger stent expansion and enhanced stent design2
  • Slimmer catheter profile with integrated one-piece shaft5
  • Low crossing forces and excellent pushability6
  • Improved catheter hub5
  • New and improved stent design for 48-mm sizes7

These new features can help clinicians treat the increasingly wide range of lesions encountered in real-world patients.

XIENCE Skypoint™ Stent Retains Proven Design Elements

Compared to other DES, several key factors account for XIENCE™ Stent’s unparalleled clinical outcomes.1

Innovative Stent Design:

The XIENCE™ Stent is designed to conform to vessel anatomy,8 as well as to reduce inflammation and minimize thrombogenicity.9 Get more details about the stent design.

XIENCE Skypoint™ Stent includes proven design elements: innovative stent design, anti-thrombotic fluoropolymer, and market-leading everolimus drug.

Anti-Thrombotic Fluoropolymer:

Unlike other stents’ polymer coatings, the Abbott fluoropolymer interacts with blood proteins in a manner that reduces thrombus formation.9 View the visual evidence of fluoropolymer safety—significantly less inflammation and thrombus formation—compared to competitors’ stents.

XIENCE Skypoint™ Stent includes proven design elements: innovative stent design, anti-thrombotic fluoropolymer, and market-leading everolimus drug.

Market-Leading Everolimus:

The choice for XIENCE™ Stent is the drug everolimus. This broadly therapeutic drug is safe and stable over the long term.10 See how the everolimus elution correlates to the restenosis cascade.

XIENCE Skypoint™ Stent includes proven design elements: innovative stent design, anti-thrombotic fluoropolymer, and market-leading everolimus drug.

Take a deeper look into Xience Skypoint™ Stents

See more detail about XIENCE Skypoint™ Stent expansion, deliverability, and successful patient outcomes, not only during the PCI but far into the future.4

  • Manuals & Technical Resources
  • Cardiovascular Products
  • Customer Service

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Data on file at Abbott.
  3. Tests performed by and data on file at Abbott—3.0 x 18 mm or 20 mm stents tested using a simulated arterial model. Comparison is between XIENCE Skypoint™ Stent, XIENCE Sierra™ Stent, Synergyǂ and Resolute Onyxǂ. Push efficiency comparison is between XIENCE Skypoint™ 48-mm Stent, XIENCE Xpedition™ 48-mm Stent and Synergyǂ 48 mm.
  4. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146.  Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333.
  5. Data on file at Abbott.
  6. Tests performed by and data on file at Abbott. Crossing force comparison is between XIENCE Skypoint™ Stent, Synergyǂ and Resolute Onyxǂ—3.0 x 18 mm or 20 mm stents tested. Push efficiency comparison is between XIENCE Skypoint™ Stent, XIENCE Xpedition™ Stent, and XIENCE Synergy™ Stent.
  7. Data on file at Abbott.
  8. Colombo A, et al. J Am Coll Cardiol. 2002;40:1021-1033.
  9. Jinnouchi H, et al. J Am Coll Cardiol. 2019;74:(Suppl B):TCT-291.
  10. XIENCE Skypoint™ Stent IFU. Data on file Abbott.

MAT-2107569 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.